These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 25108408)

  • 1. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
    Miše BP; Telesmanić VD; Tomić S; Šundov D; Čapkun V; Vrdoljak E
    Pathol Oncol Res; 2015 Apr; 21(2):347-56. PubMed ID: 25108408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of E-cadherin in patients with advanced serous ovarian cancer.
    Bačić B; Haller H; Mrklić I; Košta V; Čarić A; Tomić S
    Arch Gynecol Obstet; 2013 Jun; 287(6):1219-24. PubMed ID: 23269354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of MAPK, Topo IIα and E-cadherin immunoexpression in ovarian serous carcinomas.
    Sundov D; Petric Mise B; Mrklic I; Bacic B; Vrdoljak E; Tomic S
    Neoplasma; 2017; 64(2):289-298. PubMed ID: 28052682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma.
    Ho CM; Cheng WF; Lin MC; Chen TC; Huang SH; Liu FS; Chien CC; Yu MH; Wang TY; Hsieh CY
    Int J Gynecol Cancer; 2010 Dec; 20(9):1490-7. PubMed ID: 21119364
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions.
    Davidson B; Holth A; Hellesylt E; Tan TZ; Huang RY; Tropé C; Nesland JM; Thiery JP
    Hum Pathol; 2015 Jan; 46(1):1-8. PubMed ID: 25455994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of E-cadherin immunoexpression in patients with primary ovarian carcinomas.
    Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Lopes CS
    Ann Oncol; 2004 Oct; 15(10):1535-42. PubMed ID: 15367415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy.
    Smoter M; Bodnar L; Grala B; Stec R; Zieniuk K; Kozlowski W; Szczylik C
    J Exp Clin Cancer Res; 2013 Apr; 32(1):25. PubMed ID: 23631819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and predictive values of Nrf2, Keap1, p16 and E-cadherin expression in ovarian epithelial carcinoma.
    Liew PL; Hsu CS; Liu WM; Lee YC; Lee YC; Chen CL
    Int J Clin Exp Pathol; 2015; 8(5):5642-9. PubMed ID: 26191276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase.
    Grabowski JP; Harter P; Heitz F; Pujade-Lauraine E; Reuss A; Kristensen G; Ray-Coquard I; Heitz J; Traut A; Pfisterer J; du Bois A
    Gynecol Oncol; 2016 Mar; 140(3):457-62. PubMed ID: 26807488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic and predictive value of syntactic structure analysis in serous carcinoma of the ovary.
    Palmer JE; Sant Cassia LJ; Irwin CJ; Morris AG; Janssen EA; Baak JP; Rollason TP
    Int J Gynecol Pathol; 2008 Apr; 27(2):191-8. PubMed ID: 18317224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.
    van Baal JOAM; Van de Vijver KK; Algera MD; van der Aa MA; Sonke GS; van Driel WJ; Kenter GG; Amant FC; Lok CAR
    Gynecol Oncol; 2019 Jun; 153(3):562-567. PubMed ID: 30948193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer.
    Winkler C; King M; Berthe J; Ferraioli D; Garuti A; Grillo F; Rodriguez-Canales J; Ferrando L; Chopin N; Ray-Coquard I; Delpuech O; Rinchai D; Bedognetti D; Ballestrero A; Leo E; Zoppoli G
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549724
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low MAD2 expression levels associate with reduced progression-free survival in patients with high-grade serous epithelial ovarian cancer.
    Furlong F; Fitzpatrick P; O'Toole S; Phelan S; McGrogan B; Maguire A; O'Grady A; Gallagher M; Prencipe M; McGoldrick A; McGettigan P; Brennan D; Sheils O; Martin C; W Kay E; O'Leary J; McCann A
    J Pathol; 2012 Apr; 226(5):746-55. PubMed ID: 22069160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predicting Response to Standard First-line Treatment in High-grade Serous Ovarian Carcinoma by Angiogenesis-related Genes.
    Mendiola M; Redondo A; Heredia-Soto V; Herranz J; Berjón A; Hernández A; Miguel-Martín M; Crespo R; Barriuso J; Cruz P; Yébenes L; Peláez-García A; Castelo B; DE Molina AR; Feliu J; Hardisson D
    Anticancer Res; 2018 Sep; 38(9):5393-5400. PubMed ID: 30194194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
    Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of E-cadherin and beta-catenin immunoexpression with clinicopathologic features in primary ovarian carcinomas.
    Faleiro-Rodrigues C; Macedo-Pinto I; Pereira D; Ferreira VM; Lopes CS
    Hum Pathol; 2004 Jun; 35(6):663-9. PubMed ID: 15188131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Survival and prognostic factors in patients with recurrent low-grade epithelial ovarian cancer: An analysis of five prospective phase II/III trials of NOGGO metadata base.
    Canaz E; Grabowski JP; Richter R; Braicu EI; Chekerov R; Sehouli J
    Gynecol Oncol; 2019 Sep; 154(3):539-546. PubMed ID: 31230821
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.